341 related articles for article (PubMed ID: 16625862)
1. Neuroendocrine tumors and somatostatin: imaging techniques.
de Herder WW; Kwekkeboom DJ; Valkema R; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP
J Endocrinol Invest; 2005; 28(11 Suppl International):132-6. PubMed ID: 16625862
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor imaging for neuroendocrine tumors.
de Herder WW; Kwekkeboom DJ; Feelders RA; van Aken MO; Lamberts SW; van der Lely AJ; Krenning EP
Pituitary; 2006; 9(3):243-8. PubMed ID: 17001462
[TBL] [Abstract][Full Text] [Related]
3. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
[TBL] [Abstract][Full Text] [Related]
4. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
[TBL] [Abstract][Full Text] [Related]
5. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Jamar F; Fiasse R; Leners N; Pauwels S
J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors.
Scherübl H; Bäder M; Fett U; Hamm B; Schmidt-Gayk H; Koppenhagen K; Dop FJ; Riecken EO; Wiedenmann B
Gastroenterology; 1993 Dec; 105(6):1705-9. PubMed ID: 7902821
[TBL] [Abstract][Full Text] [Related]
8. Whole body and tomographic scan with 111In-pentetreotide: preliminary data.
Gregianin M; Macrì C; Bui F; Varotto L; Zucchetta P
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):124-6. PubMed ID: 9002769
[TBL] [Abstract][Full Text] [Related]
9. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma.
Muros MA; Llamas-Elvira JM; Rodríguez A; Ramírez A; Gómez M; Arráez MA; Valéncia E; Vílchez R
Nucl Med Commun; 1998 Aug; 19(8):735-42. PubMed ID: 9751927
[TBL] [Abstract][Full Text] [Related]
10. [Pre- and intraoperative localization of neuroendocrine tumors].
Adams S; Baum RP; Adams M; Wenisch H; Schumm-Draeger PM; Encke A; Usadel KH; Hör G
Acta Med Austriaca; 1997; 24(2):81-6. PubMed ID: 9273812
[TBL] [Abstract][Full Text] [Related]
11. Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy.
Lebtahi R; Le Cloirec J; Houzard C; Daou D; Sobhani I; Sassolas G; Mignon M; Bourguet P; Le Guludec D
J Nucl Med; 2002 Jul; 43(7):889-95. PubMed ID: 12097458
[TBL] [Abstract][Full Text] [Related]
12. Preferential localization of regional metastases from gastroenteropancreatic endocrine tumors with somatostatin-receptor scintigraphy.
MacGillivray DC; Mumtaz MA; Kurtzman SH; Spencer RP; Weiner RE; Malchoff CD
Arch Surg; 1996 Dec; 131(12):1338-42. PubMed ID: 8956777
[TBL] [Abstract][Full Text] [Related]
13. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
Shapiro B
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
[TBL] [Abstract][Full Text] [Related]
14. Comparison of labeled MIBG and somatostatin analogs in imaging neuroendocrine tumors.
Lastoria S; Maurea S; Vergara E; Acampa W; Varrella P; Klain M; Muto P; Bernardy JD; Salvatore M
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):145-9. PubMed ID: 9002775
[TBL] [Abstract][Full Text] [Related]
15. MIBG and radiolabeled octreotide in neuroendocrine tumors.
Hoefnagel CA
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):137-9. PubMed ID: 9002773
[TBL] [Abstract][Full Text] [Related]
16. Scintigraphic assessment of pituitary adenomas and several diseases by indium-111-pentetreotide.
Tumiati MN; Facchi E; Gatti C; Bossi A; Longari V
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):98-100. PubMed ID: 9002761
[TBL] [Abstract][Full Text] [Related]
17. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
[TBL] [Abstract][Full Text] [Related]
18. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: correlation with the effect of a single administration of octreotide on serum TSH levels.
Losa M; Magnani P; Mortini P; Persani L; Acerno S; Giugni E; Songini C; Fazio F; Beck-Peccoz P; Giovanelli M
Eur J Nucl Med; 1997 Jul; 24(7):728-31. PubMed ID: 9211757
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
[TBL] [Abstract][Full Text] [Related]
20. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Neuhaus C; Lenze H; Trautmann ME; Arnold R
Horm Metab Res Suppl; 1993; 27():28-35. PubMed ID: 8330869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
